Home Healthcare Pharmaceuticals Erythropoietin Drugs Market

Erythropoietin Drugs Market Size, Share & Trends Analysis Report By Product Type (Biologics, Biosimilar), By Product (Epoetin alfa, Darbepoetin alfa, Methoxy polyethylene glycol-epoetin beta), By Indication (Chronic kidney disease, Chemotherapy-induced anemia, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: October 24, 2025 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Erythropoietin Drugs Market, By Product Type 2022-2034 (USD MILLION/ Units)
    1. Biologics
    2. Biosimilar
  2. Erythropoietin Drugs Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Epoetin alfa
    2. Darbepoetin alfa
    3. Methoxy polyethylene glycol-epoetin beta
  3. Erythropoietin Drugs Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Chronic kidney disease
    2. Chemotherapy-induced anemia
    3. Others
  4. Regional Erythropoietin Drugs Market
    1. North America
      1. North America Erythropoietin Drugs Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
        2. Biosimilar
      2. North America Erythropoietin Drugs Market By Product 2022-2034 (USD MILLION/ Units)
        1. Epoetin alfa
        2. Darbepoetin alfa
        3. Methoxy polyethylene glycol-epoetin beta
      3. North America Erythropoietin Drugs Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Chronic kidney disease
        2. Chemotherapy-induced anemia
        3. Others
      4. U.S.
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      5. Canada
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
    2. Europe
      1. Europe Erythropoietin Drugs Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
        2. Biosimilar
      2. Europe Erythropoietin Drugs Market By Product 2022-2034 (USD MILLION/ Units)
        1. Epoetin alfa
        2. Darbepoetin alfa
        3. Methoxy polyethylene glycol-epoetin beta
      3. Europe Erythropoietin Drugs Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Chronic kidney disease
        2. Chemotherapy-induced anemia
        3. Others
      4. U.K.
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      5. Germany
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      6. France
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      7. Spain
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      8. Italy
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      9. Russia
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      10. Nordic
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      11. Benelux
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      12. Rest of Europe
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
    3. APAC
      1. APAC Erythropoietin Drugs Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
        2. Biosimilar
      2. APAC Erythropoietin Drugs Market By Product 2022-2034 (USD MILLION/ Units)
        1. Epoetin alfa
        2. Darbepoetin alfa
        3. Methoxy polyethylene glycol-epoetin beta
      3. APAC Erythropoietin Drugs Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Chronic kidney disease
        2. Chemotherapy-induced anemia
        3. Others
      4. China
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      5. Korea
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      6. Japan
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      7. India
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      8. Australia
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      9. Taiwan
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      10. South East Asia
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      11. Rest of Asia-Pacific
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
    4. Middle East and Africa
      1. Middle East and Africa Erythropoietin Drugs Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
        2. Biosimilar
      2. Middle East and Africa Erythropoietin Drugs Market By Product 2022-2034 (USD MILLION/ Units)
        1. Epoetin alfa
        2. Darbepoetin alfa
        3. Methoxy polyethylene glycol-epoetin beta
      3. Middle East and Africa Erythropoietin Drugs Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Chronic kidney disease
        2. Chemotherapy-induced anemia
        3. Others
      4. UAE
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      5. Turkey
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      6. Saudi Arabia
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      7. South Africa
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      8. Egypt
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      9. Nigeria
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      10. Rest of MEA
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
    5. LATAM
      1. LATAM Erythropoietin Drugs Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
        2. Biosimilar
      2. LATAM Erythropoietin Drugs Market By Product 2022-2034 (USD MILLION/ Units)
        1. Epoetin alfa
        2. Darbepoetin alfa
        3. Methoxy polyethylene glycol-epoetin beta
      3. LATAM Erythropoietin Drugs Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Chronic kidney disease
        2. Chemotherapy-induced anemia
        3. Others
      4. Brazil
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      5. Mexico
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      6. Argentina
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      7. Chile
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      8. Colombia
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
      9. Rest of LATAM
        1. Biologics
        2. Biosimilar
        3. Epoetin alfa
        4. Darbepoetin alfa
        5. Methoxy polyethylene glycol-epoetin beta
        6. Chronic kidney disease
        7. Chemotherapy-induced anemia
        8. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.